Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q4 EPS of ($0.27), $0.12 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $24.99 million versus the consensus estimate of $6.65 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.